Breast cancer

Validation of associations between ESR1 variants and breast cancer risk in Chinese cohorts

X. Li, Yao, G. Y., Li, F. X., Qiu, Y. R., Yang, X. X., Li, X., Yao, G. Y., Li, F. X., Qiu, Y. R., and Yang, X. X., “Validation of associations between ESR1 variants and breast cancer risk in Chinese cohorts”, vol. 15, p. -, 2016.

Estrogen receptor-a (ER) protein plays a key role in breast carcinogenesis, and common genetic variants in the corresponding gene locus have been associated with breast cancer risk in different populations. Here, we analyzed estrogen receptor 1 (ESR1) associations in two hospital-based studies of patients from the south of China.

Increased risk of breast cancer in individuals carrying the TNRC9 rs3803662 C>T polymorphism: a meta-analysis of case-control studies

Q. Wang, Wang, N. Y., Cao, X. M., Sun, X., Shen, D., Yuan, M., Chen, J. F., Wang, Q., Wang, N. Y., Cao, X. M., Sun, X., Shen, D., Yuan, M., and Chen, J. F., “Increased risk of breast cancer in individuals carrying the TNRC9 rs3803662 C>T polymorphism: a meta-analysis of case-control studies”, vol. 15, p. -, 2016.

Currently, the relationship between the trinucleotide repeat containing 9 (TNRC9) rs3803662 C>T polymorphism and risk of breast cancer (BC) is uncertain. Here, we attempted to obtain a more accurate assessment of this association by conducting a meta-analysis of all eligible case-control investigations, comprising 44,820 cases and 58,316 controls. A comprehensive search was performed to identify all suitable studies involving the TNRC9 rs3803662 polymorphism and BC risk.

Molecular-level effects of eribulin and paclitaxel on breast cancer based on differential co-expression network analysis

J. Qin, Chen, Y. H., Qin, J., and Chen, Y. H., “Molecular-level effects of eribulin and paclitaxel on breast cancer based on differential co-expression network analysis”, vol. 15, p. -, 2016.

We investigated the effects of eribulin and paclitaxel on breast cancer (BC) by exploring molecular biomarkers and pathways. Co-expression networks were constructed by differentially co-expressed genes and links, and centralities were analyzed to explore the hub genes. Pathway-enrichment analysis was performed. The hub genes were validated using the polymerase chain reaction and western blotting. A total of 132 and 153 differentially expressed genes were identified in BC cell lines treated with eribulin and paclitaxel, respectively.

Methylation of the RASSFIA promoter in breast cancer

Y. Ji, Jin, H. H., Wang, M. D., Cao, W. X., Bao, J. L., Ji, Y., Jin, H. H., Wang, M. D., Cao, W. X., Bao, J. L., Ji, Y., Jin, H. H., Wang, M. D., Cao, W. X., and Bao, J. L., “Methylation of the RASSFIA promoter in breast cancer”, vol. 15. p. -, 2016.

RETRACTION of “Methylation of the RASSFIA promoter in breast cancer” by Y. Ji, H.H. Jin, M.D. Wang, W.X. Cao, J.L. Bao - Genet. Mol. Res. 15 (2): gmr.15028261 (2016) - DOI: 10.4238/gmr.15028261

Subscribe to Breast cancer